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Background: The human RECQ DNA helicase family is involved in genomic stability. Gene mutations of RECQL2,
RECQL3, and RECQL4 are associated with genetic disorders and induce early aging and carcinogenesis. Although
previous studies have reported that the level of RECQL1 expression is correlated with the prognosis of some of
malignancies, the function of RECQL1 is not yet clarified. The present study aimed to examine the relationship
between prognosis and the level of RECQL1 expression in epithelial ovarian cancer (EOC), and to identify the role
of RECQL1 in EOC cells.
Methods: The level of RECQL1 expression was determined immunohistochemically in 111 patients with EOC who
received initial treatment at Hirosaki University hospital between 2006 and 2011. Effects of RECQL1 on cell growth
or apoptosis were examined in vitro using wild-type and OVCAR-3 cells (RECQL1(+) cells) and similar cells transfected
with RECQL1 siRNA transfected (RECQL1(−) cells).
Results: The level of RECQL1 expression was not related to histological type, clinical stage, or retroperitoneal lymph
node metastasis, but the expression level was significantly higher (P = 0.002) in patients with recurrence than those
without recurrence, and progression-free survival and complete response rate to chemotherapy were also improved in
patients with RECQL1-low expression (n = 39) stage III/IV EOC (P = 0.02 and P <0.05 vs RECQL1-high expression patients
(n = ), respectively). A cell proliferation and colony formation assays revealed significantly less growth of RECQL1(−) cells
compared to RECQL1(+) cells. A flow cytometry using annexin V -FITC and propidium iodide (PI) staining revealed a
significant increase in apoptotic RECQL1(−) cells. Cell cycle analysis showed a significantly greater distribution in subG1
phase indicating apoptotic cells in RECQL1(−) cells than in RECQL1(+) cells.
Conclusions: These results suggest that RECQL1 is a prognostic factor for EOC and that RECQL1 contributes to
potential malignancy by inhibiting apoptosis.
Keywords: Ovarian cancer, RECQL1, siRNA, ApoptosisBackground
Epithelial ovarian cancer (EOC) is the world’s most le-
thal gynecological cancer and the World Health
Organization Global database listed EOC as the seventh
leading form of cancer in women in 2008 [1].
Although the mean 5-year survival rate for EOC has
improved significantly over the past 30 years, the prog-
nosis remains poor, with a 46% 5-year survival rate [2].
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article, unless otherwise stated.stage of the cancer at diagnosed. The mean 5-year sur-
vival rate in advanced stages (FIGO stage III or IV) is as
low as 11% to 41% [2]. More than 70% of EOC is de-
tected in the advanced stages mainly because of a lack of
early warning signs and of reliable diagnostic tests.
Cytoreductive surgery followed by adjuvant chemother-
apy is recommended as the primary treatment for ad-
vanced EOC. Postoperatively, the combination of a
taxane and carboplatin is used as first-line chemother-
apy. EOC is highly responsive to initial anticancer treat-
ment, but approximately half of the advanced cases
recur within two years and result in poor prognosis due
to a decreased response to chemotherapy [3]. Therefore,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Patients characteristics
Clinico-pathological factors Number of patients %
Age (Median, range) yr 55 (22–84)
≤ 40 12 10.8
> 40 99 89.2
Histological type
Serous adenocarcinoma 45 40.5
Endometrioid adenocarcinoma 17 15.3
Clear cell adenocarcinoma 30 27.0










< 1.0 cm 96 86.5
≥ 1.0 cm 15 14.5
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treatment of EOC need to be identified so as to initiate
intensive treatment.
Initially found in Escherichia coli, RECQ helicase af-
fects the recombination of DNA, and deletion of RECQ
helicase causes genomic instability [4]. In addition, dele-
tion of a RECQ helicase SGS1 induces genomic instabil-
ity in yeast and shortens its life by increasing the
sensitivity to drugs that react with DNA [5]. There are
five types of RECQ helicase in humans: RECQL1, WRN,
BLM, RTS, and RECQ5 [6]. WRN, BLM, and RTS are
involved in genetic disorders associated with genomic
instability and a high incidence of cancer [7-9]. However,
the function of RECQL1 in regulation of cancer growth
is not fully clarified. A recent study has indicated that
RECQL1, a typical member of the RECQL family [10]
unwinds DNA and plays a role in chromosomal stability
[11]. Earlier studies have shown a relationship between
the level of expression or mutation of RECQL1 and the
prognosis for pancreatic cancer, liver cancer, and head
and neck cancer [12-14]. More recent study has sug-
gested a significant role of RECQL1 as a proliferative
marker in EOC [15].
The present study examined the relationship between
prognosis and the level of RECQL1 expression in EOC.
This study also identified the role of RECQL1 in cancer
cells.
Methods
Subjects and tissue samples
An immunohistochemical examination was performed
retrospectively on 111 EOCs and 10 normal ovaries sam-
ples (5 of proliferative phase and 5 of secretary phase)
from patients treated at the Hirosaki University Hospital
between 2006 and 2011. Written informed consent had
been obtained from all subjects. One slide from each
case was reviewed by a gynecologic pathologist (M.F.) to
confirm the diagnosis of EOC. The tissue specimens
included 45 serous adenocarcinomas, 17 endometrioid
adenocarcinomas, 30 clear cell adenocarcinomas, 15
mucinous adenocarcinomas, and 4 other types of carcin-
omas. All patients were primarily treated with cytore-
ductive surgery and adjuvant paclitaxel and carboplatin
(TC) chemotherapy (paclitaxel 175 mg/m2 and carbopla-
tin AUC 6). They received 6 to 9 cycles of this combined
regimen. Seventy-one of the 111 patients underwent a
staging laparotomy including a retroperitoneal lymphad-
enectomy. Optimal debulking surgery was achieved in
96 (86.5%) out of the 111 patients if defined as macro-
scopic residual tumor under 1.0 cm at the end of pri-
mary surgery, while the remaining 15 patients had a
residual tumor of greater than 1.0 cm in diameter. The
breakdown for stages of EOC consisted of 57 patients
with stage I EOC, 8 with stage II, 42 with stage III, and4 with stage IV. The duration of follow-up ranged from
21 to 92 months (median, 64 months). The mean age of
patients with EOC at surgery was 55 years old (range, 22
to 84 years old). Clinical and pathological features are
shown in Table 1. The acquisition of tissue samples was
approved by the institutional review board of Hirosaki
University’s Graduate School of Medicine.
Immunohistochemistry
The detection of RECQL1 was performed using polyclonal
antibody produced in rabbits (Santa Cruz Biotechnology,
Santa Cruz, CA). All surgical samples obtained for immu-
nohistochemistry were fixed in formaldehyde and embed-
ded in paraffin. Sections 6 μm thick were routinely passed
through xylene and a graded ethanol series. Sections were
incubated with antibody overnight 4°C after antigen re-
trieval in a sodium citrate buffer. Slides were incubated
with biotinylated species-specific secondary antibodies for
20 min and then exposed to avidin - biotinylated enzyme
complex (VECTASTAIN® Elite ABC KIT, Vector Labora-
tories, Burlingame, CA). All antibodies were detected using
0.02% chromogen diaminobenzidine (DAB) and they were
counterstained with hematoxylin. The level of RECQL1 ex-
pression was graded using staining scores, and these scores
were calculated by multiplying the intensity of nuclear
staining by the stained areas within the tumors. As shown
in Figure 1, the staining intensity of nuclei was classified as
negative (score 0), weekly positive (score 1), moderately
Negative




Figure 1 Staining intensity of RECQL1 in nuclei. No expression of RECQL1 was found in the normal ovarian tissue. The staining intensity in
EOC was graded as negative, weakly positive, moderately positive, or strongly positive. Photomicrographs are shown at 100x or 200x.
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areas were graded as follows: a score of 0 was given to a
specimen with an area of 0% staining, a score of 1 was
given to a specimen with an area of ≥1% to <25% staining,
a score of 2 was given to a specimen with an area of ≥25%
to <50% staining, and a score of 3 was given to a specimen
with an area of ≥50% staining. For each patient, a slide spe-
cimen was observed in a 0.75-mm2 field of vision using a
20× objective lens. The mean score from 3 different sites
was used as the staining score for that patient. The level of
RECQL1 expression was evaluated by 2 researchers (Y.Y.
and T.S.) who were not apprised of any physical and clinical
information. A staining score of 9 was defined as RECQL1-
high expression. Other staining scores were defined as
RECQL1-low expression.Cell line and cell cultures
OVCAR-3 was obtained from the American Type Cul-
ture Collection (Rockville, MD). This cell line is derived
from human ovarian papillary adenocarcinoma and was
grown in RPMI 1640 supplemented with 10% FCS at
37°C in a water-saturated atmosphere with 5% CO2/95%
air. OVCAR-3 was verified in writing as being ovarian in
origin. OVCAR-3 overexpresses RECQL1 [15].siRNA and RNA interference
siRNA (21 bp) targeting RECQL1 mRNA (RECQL1-
siRNA) and negative (non-silencing) control siRNA were
chemically synthesized using FlexiTube GeneSolution
GS5965 for RECQL (QIAGEN, Tokyo, Japan). Cells were
transfected with RECQL1-siRNA for 48 hours at a final
concentration of 10 nM siRNA using the Hyperfect
transfection system (QIAGEN) in accordance with the
manufacturer’s instructions. All siRNA sequences had
overhanging-3′-TT. siRNA sequences were as follows:RECQL1 siRNA sense sequence (5′-CAUUGAUCUC
UCUUAUGGAtt -3′),
RECQL1 siRNA antisense sequence (3′-ggGUAAC
UAGAGAGAAUACCU -5′),
control siRNA sense sequence (5′-AGGUCGAGAUG
ACAUGAAAtt -3′), and
control siRNA antisense sequence (3′- ggUCCAGCU
CUACUGUACUUU -5′).Real-time quantitative PCR
Total RNA was extracted from cells using an Illustra
RNAspin Mini RNA Isolation Kit (GE Healthcare,
Piscataway, NJ). Total RNA (5 μg) served as a template
for single-strand cDNA synthesis in a reaction using an
iScript Advanced cDNA Kit (Bio-Rad, Hercules, CA)
under previously described conditions [16] with slight
modifications. A CFX96 real-time PCR detection system
(Bio-Rad) was used for quantitative analyses of RECQL1
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).





GAPDH-F (5′-CCTCCCGCTTCGCTCTCT -3′), and
GAPDH-R (5′- GCTGGCGACGCA AAAGA -3′)
The primers were used at a concentration of 300 nM.
Amplification conditions were as follows: 30 seconds at
95°C, followed by 95°C for 5 seconds, and 60°C for
30 seconds for 40 consecutive cycles. After amplification,
a melting curve from 65°C to 95°C at 0.5°C increments
and 5 seconds per step was generated with continuous
monitoring of fluorescence. CFX manager Version 2.1
software (Bio-Rad) was used to create the melting curves
and quantitatively analyze data. The level of RECQL1








I/II 65 5 (7.7%)
III/IV 46 7 (15.2%) Not
significant
Histological type




Clear cell adenocarcinoma 30 1 (3.3%)
Mucinous adenocarcinoma 15 2 (13.3%)
Others 4 1 (25%) Not
significant
Retroperitoneal lymph node
metastases (n = 53)
(−) 46 1 (2.2%)
(+) 7 1 (14.3%) Not
significant
Relapse
(−) 73 5 (6.8%)
(+) 38 7 (18.4%) P = 0.002
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mRNA.
Western blot analysis
Cell lysates (50 μg protein) were prepared from OVACAR-
3 cells transfected with RECQL1-siRNA or control siRNA
(as control), electrophoresed through a 12.5% sodium dode-
cyl sulfate polyacrylamide gel, and blotted as described
previously [16]. The protein concentration was determined
using Bradford’s method. The blots were probed with the
following diluted antibodies for 2 hours: RECQL1 (Santa
Cruz Biotechnology) at 1:1000 and β-actin (Sigma-Aldrich,
St Louis, MO)) at 1:2000. The membranes were then
incubated for 1 hour with the appropriate biotinylated sec-
ondary antibodies, transferred to avidin-biotin-peroxidase
complex reagent, and incubated in this solution for 30 mi-
nutes. DAB was used as a substrate.
Cell count
OVCAR-3 cells (1 × 104 cells) were cultured in 6-well
plates as described in Cell line and cell culture. Cell counts
were performed 24 hours, 48 hours and 72 hours after
OVACAR-3 cells were transfected with RECQL1-siRNA
or control siRNA (as control). To distinguish live and dead
cells, cells were stained with 0.3% trypan blue solution
(Wako Pure Chemical Industries, Osaka, Japan). Cells
were counted in a hemocytometer. The cell count was
performed in triplicate, and the total cell count and the
number of dead cells were represented as averages.
Colony formation assay
Single-cell suspensions (50 cells) of OVCAR-3 in
RPMI1640 (10% FBS) were seeded in 6-well plates.
OVCAR-3 cultures were fixed in 6% glutaraldehyde
and stained with 0.5% crystal violet at day 7 [17]. The
stained cultures were analyzed by microscopy, and
aggregates containing 50 or more cells were counted
as colonies. The number of colonies per well was
counted. This assay was performed in triplicate.
Determination of apoptotic cells
Apoptotic or necrotic cells were determined using flow cy-
tometry with an Annexin V-FITC kit (Beckman Coulter,
Fullerton, CA). Cells were harvested and washed with cold
PBS. Cells were re-suspended with 100 μL annexin-V
binding buffer and then incubated with 10 μL annexin-V
for 15 min at room temperature in darkness. Four hun-
dred μL binding buffer containing 5 μL propidium iodide
(PI) was added to the cells and cells were incubated on ice
for 15 min. The cells were applied to a FACS Calibur-500
flow cytometer within 1 hr of preparation. A total of 1 ×
104 cells were analyzed in each sample. Evaluation was
done 24 hours after transfection of RECQL1-siRNA or
control siRNA. The results were interpreted as follows:Cells that were annexin V(−)/PI(−) (lower left quadrant)
were considered as living cells; annexin V(+)/PI(−) (lower
right quadrant) as apoptotic cells; annexin V(+)/PI(+)
(upper right quadrant) as necrotic cells; and annexin V
(−)/PI(+) (upper left quadrant) may be bare nuclei, cells in
late necrosis, or cellular debris. Experiments were repeated
in triplicate.Cell cycle analysis
Cell cycle was determined using flow cytometry with a Cell
cycle phase determination kit (Cayman Chemical, Ann
Arbor, MI). For the cell cycle assay, 1 × 105 cells were
seeded in 6-well plate. Evaluation was done 24 hours after
transfection of RECQL1-siRNA or control siRNA. Cells
were harvested and fixed gently by adding 75% ethanol and
placing at −20°C for 4–16 h. The cells were washed twice
with PBS, resuspended in 300 μl PBS containing 100 μg/ml
PI and 0.1 mg/ml RNase, incubated for 30 min at room
temperature in dark, and analyzed using a flow cytometer.
FlowJo 7.1.0 software (Tree Star, Ashland, OR) was used for
data analysis and at least 10,000 cells were counted for each
measurement. Experiments were repeated in triplicate.Statistical analysis
All statistical analyses were performed using SPSS

























Figure 2 Comparison of the prognosis between RECQL1-high and RECQL1-low patients with stage III/IV EOC. There were 7 RECQL1-high
patients and 39 RECQL1-low patients. There was significant difference in PFS between RECQL1-high (Median PFS; 12.0 months) and RECQL1-low
patients (Median PFS; 18.0 months) (HR; 0.26, 95% CI; 0.38-0.70, P = 0.02).
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were analyzed using a chi-square test. Progression-free
survival (PFS) was defined as the period from the end
of the first-line regimen to initiation of the second-
line regimen after signs of recurrence were verified in
imaging. Overall survival (OS) was calculated from the
date of the start of treatment to the date of death
or last follow-up. Cumulative survival curves were
estimated using the Kaplan-Meier method. Survival
curves were compared using the log-rank test. Vari-
ables with effect on PFS in univariate analysis were
included in the Cox proportional hazard regression
model. Multivariate logistic regression was used to
calculate hazard ratios (HRs) and 95% confidence in-
tervals (95% CIs) after controlling simultaneously
for potential confounders. Variables considered in the
models were age, histological types, residual tumor,Table 3 Univariate and multivariate analyses for determining




> 40 (n = 4) vs. ≤40 (n = 42) 46 3.44 0.5
Histological type
Serous (n = 29) vs. non-serous (n = 17) 46 1.96 0.8
Residual tumor
< 1.0 cm (n = 32) vs. ≥1.0 cm (n = 14) 46 1.12 0.5
Lymph nodes status
Negative (n = 16) vs. Positive (n = 14) 30 2.64 0.4
RECQL1 expression status
High (n = 7) vs. Low (n = 39) 46 0.26 0.3
Abbreviation: No., number of the patients; HR, hazard ratio; CI; confidence interval.
Multivariate analysis was adjusted for age, histological types, residual tumor and RE
patients who underwent lymph node dissection was insufficient.lymph node status and RECQL1 expression status. Other
differences were analyzed by Student’s t-test. Statistical
significance was set at P <0.05.
Results
Relationship between clinicopathological factors and the
level of RECQL1 expression
Immunohistochemistry showed that RECQL1 was not
expressed in the celomic epithelium, epithelium lining
inclusion cyst or the stroma of the normal ovaries
(Figure 1). Of the 111 EOCs, 12 were RECQL1-high ex-
pression. No significant correlation was noted between
the level of RECQL1 expression and clinical stage, histo-
logical type, and retroperitoneal lymph node metastasis.
However, the level of RECQL1 expression was signifi-
cantly higher (P = 0.002) in patients with recurrence than
in those without recurrence (Table 2). PFS and OS didprognostic factors of progression free survival in stage
Multivariate
% CI P value HR 95% CI P value
9-1.76 0.59 2.56 0.33-19.56 0.364
4-1.09 0.47 1.96 0.20-1.28 0.152
0-1.05 0.34 0.36 0.14-0.90 0.031
6-1.42 0.10
8-0.70 0.02 0.35 0.14-0.86 0.022
CQL1 expression status except for lymph nodes status because number of the









Complete response 36 3 (8.3%)
Partial response 10 4 (40%) < 0.05
Stable disease
Progressive disease
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high patients when all stages of disease were analyzed
(data not shown). PFS of stage III/IV diseases was sig-
nificantly longer in RECQL1-low patients (n = 39) than
RECQL1-high ones (n = 7) (Figure 2, HR; 0.26, 95% CI;
0.38-0.70, P = 0.02), but OS did not differ significantly
for the 2 groups (data not shown).
Furthermore, univariate and multivariate analyses were
performed in relation to PFS and clinico-pathological
factors including RECQL1 expression status in stage III/
IV EOC. Univariate analysis showed a significantly close
association of high RECQL1 expression with PFS, and
then, multivariate analysis suggested that high RECQL1
expression as well as a greater residual tumor could be a






























Figure 3 Determination of RECQL1 mRNA expression in OVCAR-3 cell
RECQL1 mRNA expression was significantly decreased in OVCAR-3 cells tran
control siRNA. *P <0.001 vs. control. Western blot inserted here confirmedRelationship between the level of RECQL1 expression and
the sensitivity to anticancer drugs
The sensitivity to anticancer drugs was evaluated in 46 pa-
tients with stage III/IV disease. Complete remission (CR)
was defined as disappearance of lesions on diagnostic im-
aging along with a negative result for tumor markers after
completion of the scheduled therapy. Of 46 patients, 36
patients achieved CR and 10 did partial response at best
(Table 4). Of 36 subjects with CR, only 3 (8.3%) were
RECQL1-high, while of 10 subjects without CR, 4 patients
(40.0%) were RECQL1-high (Table 4, P <0.05), suggesting
that the level of RECQL1 expression may be involved in
chemo-resistance. However, no significant difference was
found between the histological type and the rate of CR.
Thus, the clinical studies have suggested that the expres-
sion of RECQL1 would elicit sensitivity of cancer cells to
chemotherapy and elongate CR duration.
Transfection efficiency of siRNA targeting RECQL1
In order to clarify the effects of RECQL1 on cancer cell
growth, following in vitro studies were conducted. First, the
transfection efficiency of RECQL1-siRNA was examined by
determining the RECQL1 mRNA expression in OVCAR-3
cells. Expression of RECQL1 mRNA decreased signifi-
cantly in OVCAR-3 cells transfected with RECQL1-*
s by RT-PCR after transfection of RECQL1-siRNA or control siRNA.
sfected with RECQL1-siRNA compared to those transfected with
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24 hous 48 hours 72 hours
Number of total cells
RecQL1(+)
RecQL1(-)




Figure 4 Comparison of the number of total or dead OVCAR-3 cells at a time course of 24 hours to 72 hours after transfection. OVCAR-
3 cells (1 × 104 cells) were cultured in 6-well plates. While the number of the total cells is significantly smaller in the RECQL1(−) cells than in the
RECQL1(+) cells at 72 hours after transfection, the number of the dead cells is significantly greater in the RECQL1(−) cells than the RECQL1(+) cells
at 24 to 72 hour after transfection. *P <0.05.
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transfected with control siRNA (RECQL1(+) cells)
(Figure 3, P <0.001). Western blot also showed a dis-
appearance of RECQL1 protein in RECQL1(−) cells
(Figure 3).
Comparison of the growth of RECQL1(−) and RECQL1(+)
cells
While the number of the total cells is significantly lower
in the RECQL1(−) cells than in the RECQL1(+) cells at
72 hour after transfection, the number of the dead cells
is significantly higher in the RECQL1(−) cells than the



















Figure 5 Comparison of the number of colonies of OVCAR-3 cells at d
no colonies of 50 or more RECQL1(−) cells were found at day 7 after transf
of RECQL1(+) and RECQL1(−) cells at 400x (right figure). ‡ P <0.0000 vs. REC(Figure 4). In addition, while colonies of RECQL1(+) cells
increased with time, no colonies of 50 or more RECQL1
(−) cells were found at day 7 after transfection (Figure 5,
left). RECQL1(+) cells formed colonies in a cobblestone
fashion. RECQL1(−) cells were weakly linked and were in
smaller clumps than RECQL1(+) cells (Figure 5, right).Comparison of apoptosis in RECQL1(−) and RECQL1(+) cells
Double staining methods with annexin V and PI clearly
demonstrated that RECQL1(+) cells were more live and
less apoptotic at 24 hours after transfection (P <0.05 and
0.01, respectively) (Table 5), suggesting that inhibition of(-)
RecQL1(+) cells at day 7 after transfection
RecQL1(-) cells at day 7 after transfection
ay 7 after transfection. While colonies of RECQL1(+) cells increased,
ection (left figure). The photomicrographs show formation of colonies
QL1(+).
Table 5 Results of fluorescent double staining of cell
membranes and nuclei analyzed by flow cytometry
Fluorescent double staining RECQL1 (+) RECQL1 (−) P value
Annexin V(−)/PI(−)
(Live cells)
9133 ± 93.0 8863 ± 121.3 < 0.05
Annexin V(+)/PI(−)
(Apoptotic cells)
160 ± 10.0 427 ± 42.3 < 0.01
Results represent means ± SD. Experiments were repeated thrice.
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OVCAR-3 cells.
Comparison of cell cycle distribution in RECQL1(−) and
RECQL1(+) cells
As shown in Figure 6, cell cycle analysis showed a sig-
nificantly greater distribution in subG1 phase indicating
apoptotic cells in RECQL1(−) cells than in RECQL1(+)
cells. (P <0.0005). A significant difference was not found
in G2/M phase between RECQL1(−) and RECQL1(+)
cells, suggesting that inhibition of the expression of
RECQL1 induces apoptosis but does not increase G2/M
phase in which mitotic arrest (mitotic catastrophe) occurs.
Discussion
Although significant association was not found between
levels of RECQL1 expression and clinical background
such as histological type, clinical stage, and retroperiton-


















Cell phase distribution RECQL1 (+
subG1 (apoptosis) 4.5 2.
Dip G1 phase 80.2 5
S phase 8.0 0.
Dip G2/M phase 7.3 0.
Figure 6 Cell cycle distribution in RECQL1(+) and RECQL1(−) cells. Cel
phase (apoptosis) in RECQL1(−) cells than in RECQL1(+) cells. Results repres
Not significant.study have shown a close relationship between the re-
currence of EOC and the level of RECQL1 expression.
In addition, PFS of patients with RECQL1-high EOC
was significantly shorter than that of RECQL1-low pa-
tients at stage III/IV EOC. Previous studies have shown
that RECQL1 is expressed at high levels in cancer cells
with rapid growth, while RECQL1 is expressed at low
levels in cells at resting stage [18]. In addition, the higher
level of expression of RECQL1 is shown in hepatic can-
cer at high grade [13]. Because non-malignant liver tis-
sue has slight staining, it is proposed that RECQL1 can
be a molecular marker that predicts malignancies and
progression of liver cancer [13]. Sanada et al. demon-
strated that high expression of RECQL1 is correlated
with a high Ki-67 labeling index and that it can be a
marker of high proliferation in ovarian cancer tissue
[15]. Although we did not examine the relationship be-
tween expression of RECQL1 and cell growth such as
Ki-67 labeling index in our subjects, we showed that
high expression of RECQL1 was correlated with a sig-
nificantly shorter PFS in stage III/IV EOC. Recurrence is
a critical issue that worsens prognosis. Therefore, deter-
mination of RECQL1 can be a useful marker for plan-
ning strategy of tailor-made treatment.
The present study showed a close relationship between
a high level of RECQL1 expression and resistance to
chemotherapy in stage III/IV EOC. All patients with




) (%) RECQL1(-) (%) P value
2 22.4 1.5 < 0.0005
.7 61.8 6.5 <0.05
9 9.1 0.7 NS
3 6.7 0.4 NS
l cycle analysis showed a significantly greater distribution in subG1
ent means ± SD. Experiments were repeated thrice. Dip; Diploid, NS:
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RECQL1 is expressed at high levels in cisplatin-resistant
cancer cell lines derived from moderately-differentiated
tongue squamous cell carcinoma, and they proposed
that RECQL1 may be associated with the acquisition of
cisplatin resistance [19]. The formation of DNA adducts
by cisplatin results in apoptosis, and several studies have
shown that apoptosis is attenuated in cells with exten-
sive DNA repair [20,21]. Although the EOC patients
used in this study were treated with carboplatin, a plat-
inum analogue like cisplatin, expression of RECQL1 is
shown to be involved in chemo-resistance and the re-
sults of present study support previous findings that
high expression of RECQL1 attenuates the effectiveness
of platinum analogues [19].
In order to clarify the biological significance of RECQL1
expression in cell growth, RECQL1 siRNA was transfected
into OVCAR-3 cells. As shown in Figures 4, 5, and 6 and
Table 5, RECQL1 siRNA transfected-cells significantly re-
duced cell growth and increased apoptosis compared to
those of control cells. An earlier study showed increased
mitotic death (mitotic catastrophe) was prominent in a
number of cancer cells transfected with RECQL1 siRNA
[12]. Mitotic catastrophe occurs once the cell division
cycle that is not repaired by RECQL1 reaches the M
phase. In addition, if cancer cells expressing high levels of
DNA repair enzymes such as RECQL1 are affected by
specific and rapid silencing via RECQL1 siRNA, cancer
cells retaining DNA abnormalities proceed to the M phase
of the cell division cycle and mitotic arrest (mitotic
catastrophe) occurs in the M phase. However, the present
study did not show an increased cell distribution of the M
phase in which mitotic catastrophe occurs in RECQL1
siRNA transfected-cells. It is suggested in this study
that OVCAR-3 cells with decreased RECQL1 expression
yielded to apoptosis. Arai et al. reported that transfection
of RECQL1 siRNA in the presence of cisplatin caused
apoptosis of cancer cells [14]. Ngan et al. indicated that
the anticancer drug oxaliplatin causes both mitotic catas-
trophe and apoptosis [22]. Although the mechanisms of
cell death, including apoptosis, mitotic catastrophe, and
necrosis, still need to be elucidated [23], results of the
present study suggest that silencing RECQL1 induces
apoptosis.
In earlier studies, reduction of RECQL1 expression in
cancer cells through using siRNA showed an inhibitory
effect on growth of cancer in vivo [12,24]. In contrast,
normal cells were not affected by the silencing of
RECQL1 [12]. This fact may signal a breakthrough for a
new strategy to treat malignant tumors including ovarian
cancer. Induction of apoptosis is an important part of
designing anticancer drugs. RECQL1 induces apoptosis,
so drug discovery targeting RECQL1 is a promising area
for future research.Competing interests
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